The Silver Lining of Last Week's Hims & Hers Earnings Miss

Summary

When Hims & Hers Health NYSE: HIMS reported Q1 FY2026 earnings on May 11, shareholders were dismayed by the magnitude of the double miss. The telehealth platform reported an earnings per share (EPS) of negative 44 cents versus analyst expectations of four cents, and quarterly revenue of just over $608 million fell far short of the nearly $617 million consensus.Get Hims & Hers Health alerts:Sign Up While that revenue figure failed to inspire investors, it was EPS that equated to a bottom-line miss of more than 1,000% that caught the market off guard, causing the stock to sell off sharply. Since its Q1 earnings call, the stock has plunged nearly 23%. Hims & Hers Health, Inc. (HIMS) Price Chart for Thursday, May, 21, 2026 But, for buy-and-hold investors, the long-term investment thesis remains intact. The company is operating at the intersection of multiple high-growth markets that favor its international expansion efforts, it continues to demonstrate strong revenue growth, and its GLP-1 strategic partnership with Danish multinational pharmaceutical company Novo Nordisk NYSE: NVO—maker of semaglutide weight loss drugs Wegovy and Ozempic—should begin to bear fruit as soon as the second quarter. Global Demand Bodes Well for International ExpansionHims & Hers Health TodayHIMSHims & Hers Health$23.53 +0.49 (+2.12%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$13.74▼$70.43Price Target$29.37 Hims & Hers operates in five principal segments: Sexual Health, Hair Care, Dermatology, Mental Health, and Weight Loss. All five of those businesses fall into telehealth, a global market that is forecast to undergo a compound annual growth rate (CAGR) of nearly 25% from 2025 to 2030, according to industry consultancy firm Grand View Research. Yet each of its five principal segments is also poised for substantial growth. During the same forecast period, Grand View Research projects: Collectively, those global markets' forecasted gr...